An allelic variation in the IL-21 receptor can result in reduced IFN-γ production in individuals and can require administration of different doses of IL-21 to achieve therapeutic effects seen individuals that do not have the allelic variant. Based on the genotype of a patient's IL-21 receptor allele, methods of predicting therapeutic response to treatment with IL-21 are disclosed. Also disclosed are methods of selecting a therapeutic regimen for use of IL-21 in patients with variant IL-21 receptor alleles.
申请公布号
AU2006299141(B2)
申请公布日期
2011.11.24
申请号
AU20060299141
申请日期
2006.09.22
申请人
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)